Navigation Links
Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
Date:12/19/2007

Only Product of its Kind in Europe to Offer up to Six Months of Pain Relief

in OA Knee Pain

CAMBRIDGE, Mass., Dec. 19 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that it has been granted European approval through a CE mark for Synvisc-One(TM), the single treatment of Synvisc(R) (hylan G-F 20) that has been shown in the European Union to provide up to six months of proven pain relief from osteoarthritis (OA) of the knee. Synvisc-One is now the only viscosupplementation product available in Europe that is labeled to provide this long-term duration of pain relief from a single injection.

Genzyme believes that Synvisc-One will simplify osteoarthritis pain management and provide added patient convenience, while reducing the overall cost of therapy associated with multiple injections and offering a treatment option that will expand the benefits of viscosupplementation to a broader number of patients.

"The European approval of Synvisc-One is based on positive clinical data which demonstrated that combining three doses of Synvisc in a single treatment is safe and effective in providing pain relief for up to six months in patients with knee osteoarthritis," stated Ann Merrifield, president of Genzyme Biosurgery, the business unit of Genzyme Corp. that manufactures and markets Synvisc. "Delivering the benefits of Synvisc through one treatment rather than three will provide additional options for physicians and their patients to reduce the cost and burden of multiple injections."

Genzyme will also pursue marketing approvals for Synvisc-One in wider geographies in Canada, Asia and Latin America based on the European CE mark approval.

Synvisc is currently deliver
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... 16, 2014  Vermillion, Inc. (NASDAQ: VRML ... today announced the next step in its expanded strategy ... provider with the naming of current Chief Operating Officer, ... Officer, while current Chairman of the Board and CEO ... Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... -- Good computer security requires careful attention not just to ... to Debbie Christofferson, president of Sapphire Security Services . ... it open a crack, or are all your windows open? ... conference in Milwaukee . , ,Referring to the title of ...
... MADISON - Some of the first data from a new ... and by analogy galaxies in general - is making new ... , ,The findings from NASA's Spitzer Space Telescope were announced ... Edward Churchwell, a University of Wisconsin-Madison astronomer and the leader ...
... Sonic Foundry s Mediasite have a home ... help organizations capture presentations digitally and publish them on the ... for Mediasite, the companies announced in statements released in tandem ... can leverage the power of rich media communications without the ...
Cached Biology Technology:Expert says network security is about people, not just computers 2Milky Way churning out new stars at a furious pace 2Milky Way churning out new stars at a furious pace 3BxVideo designs Web hosting service for Sonic Foundry media presentations 2
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... DETROIT Diabetes Mellitus (DM), a metabolic disorder that ... chronic hyperglycemia that disrupts carbohydrate fat and protein metabolism ... both. DM can cause long-term damage, dysfunction and even ... may develop corneal complications and delayed wound healing. This ...
... Nuclear Magnetic Resonance (NMR) Spectroscopy is an extremely powerful ... by chemists from its origin, it is now essential ... scope extended in biological laboratories. Coupled with NMR, ... the enhancement of NMR signals from a wide range ...
... to five protective antigens, the presence of which are critical to ... been present in almost all isolates of Bordetella pertussis ... more than half of them, according to a paper published ahead ... "These findings tell us that there is an evolutionary advantage to ...
Cached Biology News:Wayne State discovers potential treatment for skin and corneal wound healing in diabetics 2A powder to enhance NMR signals 2Whooping cough vaccine antigen disappearing from bacteria in US 2
...
... contains the basic components required for the ... and recombinant rat Thymus Chemokine-1 in cell ... sufficient materials to run ELISAs on approximately ... conditions are met: The assay ...
Blimp-1 (H-150)...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: